CSRC probes *ST Jiuding and Kangzhi Pharmaceutical for disclosure violations
On September 18, the China Securities Regulatory Commission (CSRC) opened formal investigations into A-share companies *ST Jiuding and Kangzhi Pharmaceutical for suspected information disclosure violations. *ST Jiuding’s probe stems from inaccurate accounting of inventory and investment properties for 2023–2024, after it corrected net profit from a positive RMB 15.3 million to a loss of RMB 118 million for 2023. Kangzhi Pharmaceutical, a pediatric drug maker with a market cap of about RMB 2.9 billion, also disclosed an investigation without specifying reasons. Both companies stated they will cooperate.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page reads the event directly, while its address stays stable when the title changes.
- Summary covers the current reports
Cross-source coverage
Common ground
- Both sides agree that the CSRC investigation into *ST Jiuding is a necessary response to accounting errors.
- Both acknowledge that the company misstated inventory and investment property values for two consecutive years.
- Both agree that the company's pivot to robotics is strategically aligned with China's industrial policy.
Points of contention
- Eastern Agent sees the investigation as proof of market maturity and proactive enforcement, while Neutral Agent views it as reactive damage control after a systemic failure.
- Eastern Agent argues the two-year gap shows thoroughness, while Neutral Agent says it reveals slow response and failed gatekeepers.
- Eastern Agent claims the company's self-correction shows a healthy system, while Neutral Agent notes the restatement came after the investigation was announced.
Blind spots
- Neither side fully addresses why the company's auditors failed to catch the errors for two years, especially given its *ST watchlist status.
- Both overlook the potential impact on smaller investors who may lack resources to interpret these signals.
- The debate doesn't consider whether the CSRC's enforcement resources are adequate to monitor all flagged companies effectively.
WorldAttention’s read
The debate centers on whether the CSRC investigation into *ST Jiuding's accounting errors is a sign of market maturity or a cleanup operation after a failure. Eastern Agent argues it shows a maturing system that enforces rules consistently, while Neutral Agent insists it reveals weak gatekeepers and a slow regulatory response. Both agree the investigation is necessary, but they disagree on what it says about China's capital markets. The key blind spot is why the company's auditors and internal controls missed the errors for two years, especially for a company already flagged for financial distress. Ultimately, the investigation is a positive step, but it doesn't prove the system prevents problems—only that it can respond when they surface.
Reporting timeline
CSRC Investigates *ST Jiuding and Kangzhi Pharmaceutical for Suspected Disclosure Violations
On September 18, the China Securities Regulatory Commission (CSRC) placed two A-share listed companies under formal investigation. *ST Jiuding (600053) received a notice of case filing due to inaccurate accounting for inventory and investment properties for fiscal years 2023–2024, suspected of violating information disclosure regulations. The company had previously corrected its financial statements, adjusting 2023 net profit from RMB 15.3 million to negative RMB 118 million, and 2024 net profit from negative RMB 268 million to negative RMB 135 million. *ST Jiuding, which engages in private equity investment and real estate, is now pursuing a transformation toward robotics, having acquired Nanjing Shenyuansheng, a maker of six-axis force sensors for humanoid robots. Separately, Kangzhi Pharmaceutical (300086), a pediatric and maternal health drug maker with a market cap of about RMB 2.9 billion, also disclosed it had been placed under investigation for suspected information disclosure violations, though no specific reasons were provided.
Read sourceChina Securities Regulatory Commission Investigates *ST Jiuding and Kangzhi Pharmaceutical for Suspected Violations
On September 18, the China Securities Regulatory Commission (CSRC) placed two A-share listed companies under formal investigation. *ST Jiuding (600053) received a notice of case filing due to inaccurate accounting for inventory and investment properties for 2023-2024, suspected of violating information disclosure laws. The company had previously corrected its financial statements, adjusting 2023 net profit from RMB 15.3 million to negative RMB 118 million, and 2024 net profit from negative RMB 268 million to negative RMB 135 million. *ST Jiuding, originally in private equity and real estate, is now pursuing a strategic transformation toward robotics, having acquired Nanjing Shenyuansheng, which produces six-axis force sensors for humanoid robots. Separately, Kangzhi Pharmaceutical (300086) also disclosed it received a CSRC notice for suspected information disclosure violations, without specifying reasons. Kangzhi focuses on pediatric drugs and maternal-infant health products, with a market capitalization of approximately RMB 2.9 billion.
Read sourceChina's CSRC Files Case Against *ST Jiuding Over Accounting Inaccuracies
On September 18, 2026, *ST Jiuding announced that the China Securities Regulatory Commission (CSRC) has decided to file a case against the company for suspected violations of information disclosure regulations. The investigation stems from inaccurate accounting of inventory and investment properties for the years 2023-2024. The company stated that all its business activities are proceeding normally and that it will actively cooperate with the investigation. The announcement was made via a public filing, and the case filing marks a formal regulatory probe into the company's financial reporting practices.
Read sourceShow 5 older updatesHide older updates
China's CSRC Opens Investigation into *ST Jiuding Over Accounting Inaccuracies
On September 18, 2026, *ST Jiuding announced that the China Securities Regulatory Commission (CSRC) has initiated a formal investigation into the company for suspected violations of information disclosure regulations. The probe stems from inaccurate accounting of inventory and investment properties for the years 2023-2024. The company stated that all its business operations are proceeding normally and that it will actively cooperate with the investigation. The announcement was made via Jin10 Data, a financial news source. The investigation could lead to penalties or further regulatory actions depending on the findings.
Read sourceChina's CSRC Investigates *ST Jiuding for Inaccurate Accounting of Inventory and Properties
On September 18, 2026, *ST Jiuding (600053.SH) announced in a filing that it received an 'Investigation Notice' from the China Securities Regulatory Commission (CSRC). The CSRC has opened an investigation into the company due to inaccurate accounting of its inventory and investment properties for the years 2023-2024, which is suspected of violating information disclosure regulations. The company stated that all of its business operations are currently proceeding normally and that it will actively cooperate with the investigation during the probe period. The announcement was reported by Cailian Press (cls), a Chinese financial media outlet.
CSRC investigates *ST Jiuding and Kangzhi Pharmaceutical for disclosure violations
On September 18, the China Securities Regulatory Commission (CSRC) placed two A-share listed companies under formal investigation for suspected violations of information disclosure regulations. *ST Jiuding (600053) announced it received a CSRC notice citing inaccurate accounting for inventory and investment properties in 2023–2024. The company had previously corrected its financial statements, adjusting 2023 net profit from a positive RMB 15.3 million to a loss of RMB 118 million, and 2024 net loss from RMB 268 million to RMB 135 million. *ST Jiuding, formerly focused on private equity and real estate, is pivoting to robotics and recently acquired Nanjing Shenyuansheng, which produces six-axis force sensors for humanoid robots. Separately, Kangzhi Pharmaceutical (300086), a pediatric and maternal health drug maker with a market cap of about RMB 2.9 billion, also disclosed a CSRC investigation without specifying reasons. Both companies stated they will cooperate with the investigation.
Read sourceTwo A-Share Firms, *ST Jiuding and Kangzhi Pharmaceutical, Probed by CSRC
The China Securities Regulatory Commission (CSRC) has placed two more A-share listed companies under investigation, according to an article from East Money's securities focus. *ST Jiuding stated its operations are normal and it will cooperate with the CSRC. The company had previously disclosed errors in its financial statements for fiscal years 2023 and 2024, correcting net profit attributable to shareholders from a positive RMB 15.3 million to a loss of RMB 118 million for 2023, and from a loss of RMB 268 million to a loss of RMB 135 million for 2024. *ST Jiuding, formerly focused on private equity and real estate, is now transitioning toward six-axis force sensors for robots. Kangzhi Pharmaceutical, a pediatric and maternal health drug maker with a market cap of about RMB 2.9 billion, was also named in the investigation. The article is sourced from Securities Times Network.
Read sourceThree A-Share Companies Probed by CSRC for Information Disclosure Violations
On September 18, three A-share companies—Kangzhi Pharmaceutical, China Railway Assembly, and *ST Jiuding—announced that the China Securities Regulatory Commission (CSRC) has opened formal investigations into them on suspicion of violations regarding information disclosure. Additionally, one unnamed company and its relevant responsible persons received administrative penalty decisions. Kangzhi Pharmaceutical reported a 37.67% drop in first-half 2026 revenue to RMB 145 million and a net loss of RMB 32.77 million, narrowing from the prior year. The company stated the investigation may involve pre-change-of-control business activities, which it has since ceased. China Railway Assembly posted a 1.28% revenue increase to RMB 882 million but an expanded net loss of RMB 48.67 million. *ST Jiuding saw revenue fall 25.48% to RMB 59.89 million and an expanded net loss of RMB 88.15 million. *ST Jiuding said it does not meet mandatory delisting criteria and has accrued fines in its semi-annual report. Separately, San Te Cableway reported a 1.60% revenue decline to RMB 288 million and a 20.22% drop in net profit to RMB 53.89 million, though it was not placed under investigation.